Pinpoint Therapeutics, Inc., a Philadelphia, PA-based biopharmaceutical company focused on the development of novel autophagy inhibitors to treat cancer, raised $1 million in debt financing.

The company’s novel compounds target a recently discovered enzyme in the autophagy pathway called PPT1, which is highly expressed across most cancers.

These inhibitors could be applied to a broad range of cancers alone or in combination with other treatments to overcome therapy resistance.

Pinpoint will develop first-in-class autophagy inhibitors into clinical drugs for testing in a range of treatment-refractory cancers.

Pinpoint was launched in 2018 through PCI Ventures, a division of the Penn Center for Innovation (PCI) at the University of Pennsylvania. | To read full story, visit https://startuparound.com/read/1581503412.8031504/Pinpoint-Therapeutics-Raises-$1M-in-Seed-Funding?ref=audio_experience